Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model
A Randomized, Double-blind, Placebo-controlled Trial Assessing the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model for Enterotoxigenic Escherichia Coli (ETEC)
Sponsor: Immuron Ltd.
Listed as NCT05933525, this PHASE2 trial focuses on Diarrhea and Infectious Diarrhea and remains completed. Sponsored by Immuron Ltd., it has been updated 7 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Sep 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immuron Ltd.
- Naval Medical Research Center
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .